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Abstract
The neuromuscular system of helminths controls a variety of essential biological processes and 
therefore represents a good source of novel drug targets. The neuroactive substance, acetylcholine 
controls movement of Schistosoma mansoni but the mode of action is poorly understood. Here, we 
present first evidence of a functional G protein-coupled acetylcholine receptor in S. mansoni, 
which we have named SmGAR. A bioinformatics analysis indicated that SmGAR belongs to a 
clade of invertebrate GAR-like receptors and is related to vertebrate muscarinic acetylcholine 
receptors. Functional expression studies in yeast showed that SmGAR is constitutively active but 
can be further activated by acetylcholine and, to a lesser extent, the cholinergic agonist, carbachol. 
Anti-cholinergic drugs, atropine and promethazine, were found to have inverse agonist activity 
towards SmGAR, causing a significant decrease in the receptor’s basal activity. An RNAi 
phenotypic assay revealed that suppression of SmGAR activity in early-stage larval 
schistosomulae leads to a drastic reduction in larval motility. In sum, our results provide the first 
molecular evidence that cholinergic GAR -like receptors are present in schistosomes and are 
required for proper motor control in the larvae. The results further identify SmGAR as a possible 
candidate for antiparasitic drug targeting.
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1. Introduction
Schistosomiasis is a debilitating, chronic infection that affects over 200 million people in 74 
endemic countries. Trematodes of the genus Schistosoma are the causative agents of the 
disease [1], with S. mansoni responsible for nearly half the infections. Currently, there is a 
single therapeutic option, praziquantel, and no vaccine is available. Reports of emerging 
resistance to praziquantel [reviewed in 2], as well as its lack of efficacy against the 
migratory larval stages of the parasite [3] underpin the need to develop new therapeutic 
targets. One area that has been especially productive in the search for new drug targets is the 
parasite nervous system, exemplified by the success of ivermectin, pyrantel and the more 
recently discovered octadepsipeptides [4].
The schistosome nervous system is involved in a variety of processes that are essential to 
parasite survival including migration, attachment, feeding and reproduction [5]. It is 
hypothesized to play a role in signal transduction via synaptic and paracrine mechanisms, as 
schistosomes lack a circulatory system and thus the capability for classical endocrine 
signaling. The key interaction controlling neuronal signaling in schistosomes involves 
neuroactive compounds binding to their cognate receptors and eliciting effects directly or 
via second messenger cascades [reviewed in 6–8]. These receptors fall into two broad 
classes: the Cys-loop ligand-gated ion channels and the metabotropic, heptahelical G 
protein-coupled receptors (GPCR). Sequencing of the S. mansoni genome [9, 10] has 
provided a large complement of putative neuroreceptors from both classes. Several have 
been cloned and characterized, including receptors for dopamine, histamine, glutamate and 
serotonin [11–17]. Relatively less, however, is known about the cholinergic system of 
schistosomes.
Acetylcholine (ACh) is a quaternary amine neurotransmitter that elicits a variety of 
biological effects. In vertebrates, ACh acts primarily as an excitatory neurotransmitter and 
controls processes such as muscular contraction, glandular secretion and memory formation 
[18]. ACh plays a similar excitatory role among invertebrates and its role in nematode motor 
function is well characterized. A notable exception to the excitatory role of ACh occurs in 
schistosomes, where there is evidence of ACh acting as a major inhibitory neurotransmitter 
or modulator. Activation of ACh receptors in S. mansoni manifests as muscular relaxation 
resulting in flaccid paralysis [19, 20]. Schistosomes have several putative ACh receptors that 
may be responsible for this phenomenon [reviewed in 7]. The majority of these receptors are 
nicotinic ion channels, some of which have been cloned and characterized in vitro [21, 22]. 
However, two muscarinic cholinergic receptors are also predicted. One of these appears to 
be truncated (Smp_152540) [10] but the other has all the structural features of a full-length 
GPCR and is worthy of further investigation.
MacDonald et al. Page 2
Mol Biochem Parasitol. Author manuscript; available in PMC 2016 September 10.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Muscarinic acetylcholine receptors (mAChRs) are members of the heptahelical GPCR 
superfamily and are structurally related to rhodopsin (Family A GPCRs). They mediate their 
effects by interaction with heterotrimeric G proteins, causing changes in intracellular Ca2+ 
or cyclic adenosine monophosphate (cAMP). The term “muscarinic” is derived from these 
receptors’ preferential binding and activation by the fungal toxin muscarine [23]. There are 
5 subtypes of mAChRs in vertebrate organisms [reviewed in 24]. Vertebrate mAChRs are 
located in both the central and peripheral nervous systems and are involved in a vast array of 
physiological processes such as memory, smooth muscle contraction and regulation of 
neurotransmitter release. Invertebrate mAChRs, also known as G protein-coupled 
acetylcholine receptors (GARs), share this functional diversity with their vertebrate 
homologs. Three GAR subtypes have been identified in parasitic and free-living nematodes 
[25–28]. Similar to vertebrate receptors, they may act in either an excitatory or inhibitory 
manner and are located on neurons contributing to several important nematode activities, 
such as muscular contraction, sensory perception and reproduction. Although structural 
similarity and broad expression patterns define the invertebrate GARs and vertebrate 
mAChRs as homologs, there are significant differences in their pharmacological profiles 
[28, 29]. This unique pharmacology, combined with their functional importance, marks 
helminth GARs as promising targets for antiparasitics.
In the present work, we describe the first functional analysis of a schistosome GAR 
(SmGAR), possibly the only full-length G protein-coupled acetylcholine receptor in S. 
mansoni. SmGAR is distantly related to nematode GARs and its expression is predicted to 
be highly up regulated during the early larval stages of the parasite [10]. Functional analysis 
in a heterologous system determined that SmGAR has high basal activity, consistent with a 
constitutively active receptor, but it is further activated by cholinergic agonists. 
Furthermore, RNAi phenotypic assays revealed that silencing of SmGAR causes significant 
disruption of larval motility, suggesting a potentially important role in early parasite 
migration.
2. Materials and Methods
2.1 Parasites
Biomphalaria glabrata snails infected with a Puerto Rican strain of S. mansoni were 
generously provided by the Biomedical Research Institute and BEI Resources, MD, USA. 
Cercariae were obtained by exposing 6–8 week-old snails to bright light [30] for 2 hours. 
Cercariae were then transformed into larval schistosomulae in vitro by mechanical shearing 
[30]. Schistosomulae were washed with Opti-MEM containing antibiotics (100 μg/ml 
streptomycin, 100 units/ml penicillin and Fungizone 0.25 μg/ml) and cultured for 1–3 days 
in Opti-MEM (no antibiotics) supplemented with 6% fetal bovine serum at 37°C/5% CO2. 
Adult worms were recovered by portal perfusion [30] from adult female CD1 mice 7 weeks 
post-infection with 250 freshly shed cercariae/mouse.
2.2 Cloning of SmGAR
Total RNA was extracted from either pooled adult worms or 24-hour-old schistosomulae, 
using Trizol (Invitrogen) or the RNeasy Micro Kit (Qiagen), according to manufacturers’ 
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instructions. RNA was reverse-transcribed (RT) using MML-V and Oligo-dT primer 
(Invitrogen). A negative control reaction lacking MML-V reverse transcriptase (-RT), was 
used to rule out the possibility of contamination of cDNA with genomic DNA. Primers to 
amplify the full length, predicted coding sequence of Smp_145540 (SmGAR) were designed 
using Oligo 6.2 [31]. Primer sequences were as follows: Forward 5′-
ATGAATCTATTATTTTGTTTTC-3′ and Reverse 5′-
TTATAATCTTCTAAAATCACC-3′. A proofreading Phusion High Fidelity Polymerase 
(New England Biolabs) was used for PCR amplification according to standard protocols. 
Cycling conditions were as follows: 98°C/30s, 30 cycles of 98°C/10s, 54°C/60s, 72°C/60s 
and a final extension of 72°C/5min. All PCR products were ligated to the pJet1.2 Blunt 
cloning vector (Thermo Scientific) and verified by DNA sequencing of at least two 
independent clones.
2.3 Bioinformatics
The predicted protein sequence of SmGAR (Smp_145540) was used as a query for a 
BLASTp search of the NCBI non-redundant protein dataset. Homologs were aligned with 
SmGAR using PROMALS3D [32] and the resulting multiple sequence alignment was then 
inspected manually to ensure the correct alignment of highly conserved Family A GPCR 
transmembrane (TM) motifs. Residues of interest are described both according to their 
numerical position in the primary SmGAR sequence and the Ballesteros and Weinstein 
numbering system for Family A GPCRs [33], which is shown as a superscript. The 
Ballesteros and Weinstein designator describes the TM helix where the residue is located 
(TM 1–7) and its position within the helix relative to a reference residue. The reference is an 
invariant amino acid of each TM helix, which is arbitrarily given the number 50. Thus, for 
example, the invariant reference for TM 3 in the schistosome receptor is Arg2483.50 
(position 3.50) and Asp2303.32 is a TM 3 aspartate located eighteen residues upstream from 
the conserved reference (position 3.32). This system is used throughout the study to compare 
equivalent TM residues from different receptors. Identification of TM regions was 
performed by TMHMMv2.0 [34] and comparison of SmGAR with crystal structures of 
vertebrate GPCRs available in the general Protein Database (PDB), including the human β2-
adrenergic receptor (PDB Accession# 2rh1) and the rat M3 muscarinic receptor (4daj). A 
neighbor-joining phylogenetic tree with 1000 bootstrap replicates was built from the 
multiple sequence alignment and visualized with FigTree 3.0 (http://tree.bio.ed.ac.uk/
software/figtree/). Accession numbers of the sequences used in the alignment can be found 
in Table S1.
2.4 Yeast Expression
Full-length SmGAR was ligated into a previously described yeast expression vector, 
Cp4258 [28, 35]. The resulting construct (Cp4258-SmGAR) was confirmed by DNA 
sequencing and used to transform Saccharomyces cerevesiae strain Cy13393 (MATαPFUS1-
HIS3 GPA1-Gαi2(5) can1 far1Δ1442 his3 leu2 lys2 sst2Δ2 ste14::trp1::LYS2 ste18γ6-3841 
ste3Δ1156 tbt1-1 trp1 ura3); kindly provided by J. Broach, Penn State University). This 
strain expresses the HIS3 gene under the control of the FUS1 promoter [35] and also 
includes an integrated copy of a chimeric Gα gene in which the first 31 and last 5 codons of 
the native yeast Gα (GPA1) were replaced with those of human Gαi2 subunit. Strains 
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containing Gαq and Gαs were also tested but found to yield no receptor activity when 
compared to Cy13393. Yeast was cultured according to a previously established protocol 
[28] until mid-log phase. Yeast (200 μl) were then transformed by the lithium acetate 
method using 200 μg of carrier DNA and 1 μg of Cp4258-SmGAR or empty plasmid as a 
negative control and positive transformants were selected on synthetic complete (SC) media 
containing 2% glucose and lacking leucine (SC/leu−)
2.5 Yeast Receptor Activity Assays
The principle of the receptor activity assay is based upon the protocols of Wang et al. [35] 
as previously described [13, 14, 28]. Briefly, single colonies carrying the Cp4258-SmGAR 
construct or empty plasmid (mock control) were grown in SC/leu− overnight at 30°C, 250 
rpm. Cells were then washed 3 times in SC medium lacking leucine and histidine (SC/
leu−/his−) and finally resuspended in SC/leu−/his− supplemented with 50 mM 3-(N-
morpholino)propanesulfonic acid (MOPS), pH 6.8 and 1.5 mM 3-Amino-1, 2, 4-Triazole (3-
AT). The addition of 3-AT reduces background signaling-induced basal yeast growth by 
inhibiting the gene product of HIS3 [36]. Yeast cells were plated at a density of 3000 cells/
well to a flat-bottom 96-well plate with either test agonist at the specified concentration, 
vehicle alone, or SC/leu−/his+ media at a final volume of 200 μl and incubated at 30°C for a 
period of 24–30 hours, after which 20 μl of Alamar Blue dye (Invitrogen) was added to each 
well. Plates were returned to 30°C incubator until Alamar Blue began to turn pink (2–4 
hours) and fluorescence (560nm excitation/590 emission) was measured every 30 minutes 
for a total of 4 hours using a Synergy H4 microplate fluorometer (BioTek, USA). Baseline 
fluorescence values from cell-free wells were subtracted from test wells and fluorescence for 
each test group was normalized to water-treated control cells. All results are derived from 2–
3 experiments each with 6 replicates. Statistical analysis and curve fitting was done using 
Prism v5.0 (GraphPad Software).
2.6 Synthesis of pooled SmGAR siRNAs
A unique 219 bp fragment of SmGAR sequence was identified using BLAST analysis and 
amplified using Phusion High Fidelity Polymerase (New England Biolabs). Amplification 
primers were designed using Oligo 6.2 [31] and are as follows: Forward 5-
CGAAAACAACCAAACTTGGGG-3′ and Reverse 5′-
CGGTTTCTGGAACTTCATTTAAACG-3′. Products were ligated to pJET 1.2Blunt vector 
(Fermentas, USA) and verified by DNA sequencing. For synthesis of long double stranded 
RNA (dsRNA), a T7 promoter site (5′-TAATACGACTCACTATAGGGAGA-3′) was 
added to each end of the target fragment by PCR. The T7-flanked target sequence was used 
as a template for in vivo transcription of both DNA strands by the MegaScript T7 
Transcription Kit (Ambion), according to the manufacturer’s instructions. The resulting 
dsRNA was digested by RNAseIII (Invitrogen) and purified using a Centricon YM-30 filter 
unit (Millipore) in order to generate a heterogeneous pool of specific siRNA. The purity and 
concentration of pooled siRNA were measured using a Nanodrop ND1000 
spectrophotometer.
MacDonald et al. Page 5
Mol Biochem Parasitol. Author manuscript; available in PMC 2016 September 10.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
2.7 RNAi and Motility Assay
Cercariae were shed from snails and transformed in vitro by the standard protocol [30] with 
a slight modification. Following the final wash step, parasites were resuspended in Opti-
MEM containing no antibiotics or FBS and plated at a density of ≈100 animals/well in a 24-
well culture plate. Transfection of schistosomulae with SmGAR or non-relevant negative 
control siRNA (Silencer scrambled siRNA negative control, Ambion) was performed as 
previously described [37] in the presence of siPORT Neo FX Transfection Agent (Ambion, 
USA) at a final concentration of 50 nM. Animals were cultured for 24 hours and then 
assayed for motor phenotypes or harvested for quantitative PCR (qPCR). The principle of 
the motility assay is based upon a previously established protocol [38]. Schistosomulae were 
filmed for a period of 60 seconds using a Nikon SMZ1500 microscope equipped with a 
digital video camera (QICAM Fast 1394, mono 12 bit, QImaging) and SimplePCI version 
5.2 (Compix Inc.) software. Parasite motility was then calculated using the Fit Ellipse 
function in the ImageJ software package (version 1.41, NIH, USA), as previously described 
[38] except that the definition of a body movement was revised to include any change in 
body length (shortening or elongation) of 5% or more. Three distinct fields were recorded 
for each well and a minimum of 12 animals per treatment group were measured in each 
experiment. The data shown are the result of three independent experiments.
2.8 Quantitative PCR (qPCR)
Total RNA was extracted from siRNA-treated schistosomulae using the RNeasy Micro RNA 
Extraction Kit (Qiagen) as per manufacturer’s instructions with the following modification. 
Animals were washed in 1X phosphate-buffered saline (PBS) and resuspended in the 
provided lysis buffer prior to sonication for 1 minute (6 pulses of 10s/each), as described in 
[38]. Total RNA was then extracted from the resulting lysate and assessed for quantity and 
purity using a Nanodrop ND 1000 spectrophotometer. RT reactions were performed as 
above, using 100 ng of RNA template per reaction. Primers to amplify a unique 250 bp 
fragment separate from the region used to generate the siRNA of SmGAR were designed 
using Oligo [31] and are as follows: Forward 5′-CAGCCTGTTTAACCTCCC-3′ and 
Reverse 5′-TTGAAGATAGGGTCCGTT-3′. Quantitative real-time PCR (qPCR) was 
performed using Platinum SYBR Green UDG SuperMix (Invitrogen) in a 25 μl reaction 
volume on a RotorGene RG3000 (Corbett Life Sciences, Australia). Cycling conditions 
were 50°C/2 min, 95°C/2 min, followed by 50 cycles of 94°C/15 s, 57°C/30 s, 72°C/15 s. 
The housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Accession # 
M92359) was used as an internal control and qPCR primers were: Forward 5′-
GTTGATCTGACATGTAGGTTAG-3′ and Reverse 5′-
ACTAATTTCACGAAGTTGTTG-3′. Relative gene expression was calculated using the 
Pfaffl’s method [39]. Results shown are derived from three separate experiments, each done 
in triplicate.
2.9 Homology Modeling
Homology modeling of SmGAR was carried out using the UCSF Chimera Package 
(Computer Graphics Laboratory, University of California, San Francisco) [40] and Modeller 
v9.12 [41]. SmGAR was aligned with several GPCR crystal structures available in the 
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general Protein Database (PDB accession numbers 2rh1, 4daj, 1u19, 3eml) and the rat (R. 
norvegicus) M3 muscarinic receptor (4daj) [42] was selected as the best template, according 
to similarity scores. The alignment between SmGAR and the M3 receptor was edited to 
remove areas of low structural resolution, including portions of the N-terminal and the 
divergent third intracellular (il3) loop. Deletion of the il3 loop also removed the portion of 
the M3 structure containing the T4 lysozyme structure [42]. The default automodel feature 
of Modeller v9.12 was used for subsequent modeling steps and final evaluation of model 
accuracy. The rat M3 structure (4daj) and resulting model of SmGAR were superimposed 
using the Matchmaker tool.
3. Results
3.1 SmGAR is related to nematode and predicted flatworm GARs
SmGAR (Smp_145540) was amplified from oligo-dT reverse-transcribed cDNA using PCR 
primers that targeted the beginning and end of the predicted Smp_145540 coding sequence. 
Based on the most recent annotation of the S. mansoni genome [10], Smp_145540 spans 3 
exons and 1938 bp, which would result in a 74 kDa protein. However, the RT-PCR 
consistently amplified a longer product with a single continuous reading frame of 2805 bp 
and a predicted protein size of 106 kDa. This was confirmed by sequencing of multiple 
clones. The cloned sequence is identical to the Smp_145540 transcript except for the highly 
variable third intracellular loop region (il3), which is longer in the cloned cDNA. Further 
analysis revealed that SmGAR matches exactly the Smp_145540 genomic sequence and the 
extra bases correspond to the two predicted introns, which are retained in the SmGAR 
cDNA. The absence of amplification in the negative –RT control lacking reverse 
transcriptase rules out possible genomic DNA contamination of the sample. Thus we 
conclude that the SmGAR (Smp_145540) is expressed without introns, similar to 
mammalian Family A GPCRs [43]. We cannot, however, rule out the possibility of a shorter 
SmGAR species, possibly the product of differential splicing in the il3 loop, which could not 
be detected in this study.
In order to identify homologs, the sequence of SmGAR was used as a query for a BLASTp 
search of the NCBI non-redundant protein dataset and aligned with the resulting hits. 
SmGAR shared the highest homology with a putative GAR-2 receptor from the trematode 
Clonorchis sinensis (42%), Caenorhabditis elegans GAR-2 (44%) and Ascaris suum GAR-
like receptor (35%,). Although the C. elegans GAR shares a higher percent similarity with 
SmGAR, the Clonorchis receptor has higher coverage (96%), even across the highly 
divergent il3 loop. Putative homologs of SmGAR also appear in the genomes of the cestodes 
Taenia solium and Echinococcus granulosus [44, 45]. Phylogenetic analysis (Fig. 1) shows 
helminth (nematode and flatworm) GARs clearly diverging from vertebrate muscarinic 
receptors and the flatworm GARs form their own distinct clade within the helminth branch. 
All members of this clade, including SmGAR, have longer amino acid sequences than their 
human and nematode counterparts.
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3.2 SmGAR is a constitutively active acetylcholine receptor
The activity of SmGAR was assessed using a previously described yeast functional assay 
[28, 35]. Briefly, a plasmid containing the 2805 bp coding sequence for SmGAR was 
transformed into S. cerevesiae yeast that are auxotrophic for histidine. Activation of the 
heterologously expressed GPCR with the appropriate ligand allows for expression of the 
HIS3 reporter gene, which is coupled to the yeast endogenous pheromone pathway and 
allows the yeast to grow in histidine-deficient media. Receptor activity is then measured by 
yeast growth in selective media using the fluorometric redox indicator Alamar Blue 
(Invitrogen). Coupling to the correct guanosine nucleotide-binding protein (G protein) alpha 
subunit is important for receptor function. Therefore, yeast strains expressing different Gα 
subunits were tested and a strain expressing inhibitory Gαi (CY13393) produced the 
strongest response when compared to mock-transfected controls (not shown). This suggests 
that SmGAR couples to Gαi and agrees with our prediction of SmGAR as a GAR-2 
homolog. GAR-2 was previously described as a Gi/o-coupled receptor [26].
Further analysis of SmGAR revealed that the receptor has high basal activity when 
expressed in yeast, suggesting a propensity towards spontaneous activation (Fig. 2A). 
SmGAR-expressing cells treated with vehicle (water) exhibited high levels of receptor 
activity, whereas no measurable activity was seen in cells transformed with empty plasmid 
(mock control). Once thought of as an artifact of heterologous expression, there is mounting 
evidence for the biological relevance of constitutively active GPCRs [reviewed in 46]. 
Moreover, constitutively active GPCRs often retain their ability to respond to agonists and 
signal above their elevated baseline [47]. In order to test this, SmGAR-expressing cells were 
treated with several neuroactive substances, each at a concentration of 100 μM. The results 
show that SmGAR is significantly activated by ACh (P < 0.0001) but not biogenic amines 
(tyramine and histamine) or glutamate (Fig. 2A), suggesting the response is specific. The 
effect of ACh was seen above the elevated baseline of SmGAR and was dose-dependent 
(Fig. 2B). SmGAR could also be activated by the classical cholinergic agonist, carbachol 
(Fig. 2C) but the response was weaker than that observed with ACh.
One way to characterize the pharmacology of constitutively active receptors is through the 
use of inverse agonists. Inverse agonists are compounds that inhibit the ligand-independent 
signaling of constitutively active GPCRs [48]. Often inverse agonists act as neutral 
antagonists on non-spontaneously activated receptors. We therefore decided to test several 
known cholinergic drugs for inverse agonism on SmGAR activity. Yeast cells expressing 
SmGAR were treated with varying concentrations of atropine, promethazine or pirenzepine 
in the absence of ACh. Atropine and pirenzepine are classical muscarinic receptor 
antagonists. Promethazine has mixed antagonist activity towards muscarinic and H1 
histamine receptors [49]. The results of the functional assay show that both atropine (Fig. 
3A) and promethazine (Fig. 3B) are able to decrease the high basal activity of SmGAR in a 
dose-dependent manner, atropine being the most potent of the two. In contrast, pirenzepine 
had no significant effect up to a concentration of 100 μM. There is some inhibition by 
pirenzepine at 1mM but the effect is quite small (< 50% inhibition) (Fig. 3C). To verify that 
the drug effects were receptor-mediated and not the result of generalized cytotoxicity, cells 
were plated in non-selective media (SC supplemented with histidine) containing the highest 
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concentration of antagonist tested (1 mM). There was no inhibition of growth in these 
control cells or in the mock-transfected, antagonist-treated control cells.
3.3. SmGAR sequence analysis and homology modeling
In order to examine whether SmGAR contained unique structural features that might explain 
its high basal activity, we compared the schistosome receptor to cholinergic receptors from 
other species. A structural alignment of mAChRs and GAR-like receptors from humans, 
nematodes and other Platyhelminthes was generated. A homology model of SmGAR was 
also generated, using the crystal structure of the rat M3 muscarinic receptor (4daj) as a 
template. These results show that SmGAR has the typical heptahelical architecture of 
Family A GPCRs, and the TM regions align closely with the M3 template (Fig. 4A). The 
structural alignment identified several of the amino acids previously implicated in ligand 
binding, including the three lid-forming tyrosines of the receptor’s binding pocket (SmGAR 
Tyr2313.33, Tyr8696.51, Tyr8987.39) and the highly conserved aspartate of TM3 (SmGAR 
Asp2303.32), which is essential for binding the positively charged headgroup of ACh and 
related ligands [42]. However the analysis also revealed potentially important amino acid 
substitutions that could affect binding affinity and/or signaling activity. For example, the 
signature TM6 asparagine of mammalian muscarinic receptors (Asn6.52) [50, 51], which is 
directly involved in hydrogen bonding within the ligand binding pocket [42] is replaced with 
a histidine in SmGAR (His8706.52). Other important substitutions were detected at the 
TM3/il2 interface and the cytoplasmic end of TM6 (Fig. 4B), two regions known to play a 
key role in the conformational activation of GPCRs and subsequent G protein-coupling 
[reviewed in 50]. Of note are substitutions involving residues of the so-called “ionic lock” 
between TM3 and TM6, which stabilizes the inactive conformation of some GPCRs. The 
lock is formed in part by a salt bridge between an invariant arginine of TM3 (Arg3.50) and an 
acidic residue at the cytosolic interface of TM6 (Glu6.30) [50]. The TM3 arginine is 
conserved in SmGAR (Arg2483.50) but there is a non-conservative substitution near the 
interacting site (Phe →Cys2503.52) and the acidic residue of TM6 is replaced with an 
alanine (Glu →Ala8486.30) (Fig. 4B). As discussed later, these differences are expected to 
impact on receptor signaling activity and could contribute to the high basal activity of 
SmGAR.
3.4 SmGAR is plays a role in larval parasite motility
C. elegans GAR receptors are known to play an important role in worm locomotion [52, 53]. 
Here, we used an RNAi phenotypic assay to determine whether SmGAR has a similar 
function in schistosomes. Freshly transformed S. mansoni schistosomulae were treated with 
a pool of heterogeneous SmGAR-specific siRNA and the effect on parasite motility was 
measured with a quantitative imaging assay. The expression of SmGAR is predicted to be 
highly up-regulated in early-stage schistosomulae [10] and therefore we measured motility 
at 24 hours post-transfection with siRNAs. Animals treated with nonsense scrambled siRNA 
were also included as a negative control. Treatment with SmGAR siRNAs significantly (P < 
0.01) decreased parasite motility by approximately 70% when compared to the negative 
control (Fig. 5A) and the silencing was confirmed by qRT-PCR (Fig. 5B). Treatment with 
gene-specific siRNA completely silenced the expression of SmGAR relative to the 
scrambled siRNA control. However, there was no change in the expression of an unrelated 
MacDonald et al. Page 9
Mol Biochem Parasitol. Author manuscript; available in PMC 2016 September 10.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
gene, SmACC-1 (Accession# KF694748), indicating that suppression of SmGAR was 
specific, at least at the RNA level.
4. Discussion
Cholinergic neurotransmission is a key pathway in both nematode and flatworm motor 
control [5–7]. The effects of ACh are mediated through two types of receptors- ionotropic 
nicotinic receptors and the metabotropic muscarinic receptors or GARs. Fast cholinergic 
neurotransmission is mediated by the nicotinic receptors, which are members of the Cys-
loop superfamily of ligand-gated ion channels. These channels are typically cation-selective, 
though they can also be anion-selective in invertebrates, and are expressed both neuronally 
and directly on muscle. Due to their importance as antiparasitic drug targets, several 
nematode nicotinic receptors have been cloned and pharmacologically characterized 
[reviewed in 54]. Among the flatworms, putative cholinergic channel subunits have been 
cloned from S. haematobium [21] and we have recently described a first nicotinic chloride 
channel in S. mansoni [22].
Invertebrate GARs belong to the GPCR superfamily and are homologs of the muscarinic 
cholinergic receptors in mammals. Studies primarily of C. elegans have shown that GARs 
control a variety of processes in nematodes, including the modulation of sensory perception, 
locomotion and reproductive behaviors. Three GAR receptor subtypes have been identified 
in free-living and parasitic nematodes [25–28] and, similar to vertebrate mAChRs, GARs 
may behave in either an excitatory or inhibitory manner, depending on where they are 
expressed and signaling mechanism. It is important to note that while nematode GARs are 
activated by ACh, they display a divergent pharmacological profile compared to human 
mAChRs. This unique pharmacology and the control exerted over motor function by 
cholinergic signaling make GAR homologs found in parasitic worms potential therapeutic 
targets [28].
In comparison to nematodes, relatively little is known about the structure or function of 
GARs in flatworms. Pharmacological studies carried out on the free-living flatworm 
Dugesia do suggest the involvement of muscarinic receptors in the control of motor function 
[55] and SmGAR is the first of these receptors to be characterized in a flatworm at the 
molecular level. Our bioinformatics analysis indicate that SmGAR shares significant 
homology with known GARs from nematodes as well as predicted GARs of fellow 
Platyhelminthes, including other trematodes and recently described tapeworm sequences 
[44, 45]. Interestingly, the flatworm GARs all appear to have exceptionally long il3 regions, 
resulting in longer protein sequences than those of nematodes or vertebrates. The il3 region 
of Family A GPCRs is known to play important roles in conformational activation of the 
receptor, binding to the G protein and regulation of signaling. It will be of interest to 
determine if the increased length of the il3 among flatworm GARs impacts on receptor 
function.
SmGAR was cloned and expressed in yeast, using a previously described GPCR functional 
assay [35]. Initial studies showed that cholinergic agonists selectively activated the 
schistosome receptor, ACh being more potent than carbachol. Interestingly, our 
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investigation also showed that SmGAR was partially activated in the absence of agonist. 
Untreated SmGAR-expressing yeast cells consistently exhibited a high level of basal 
receptor activity when compared to cells transformed with empty vector, suggesting that 
SmGAR is capable of spontaneous activation. Constitutive (ligand-independent) activation 
of GPCRs has been well documented, not only in mammals but also invertebrates [56] and 
cholinergic receptors, in particular, are known to exhibit constitutive activity [46, 50]. Like 
SmGAR, these receptors can be further activated by a specific agonist (e.g. ACh) but their 
baseline is elevated. Spontaneous GPCR activity may be caused by overexpression of the 
receptor (or G protein partner) in recombinant systems. However, it is now generally 
accepted that some GPCRs have a natural propensity towards spontaneous activation and the 
resulting, continuous signaling can have important (patho)physiological consequences in 
vivo [46, 48, 57]. Extensive research into the structural basis of constitutive activity has 
identified regions of particular importance that affect inter- and intra-helical bonding 
interactions, which in turn affect the conformational shift between inactive and active states. 
One of these key regions is the well-described “ionic lock” of rhodopsin-like receptors. An 
electrostatic interaction formed between an invariant arginine of TM3 and a highly 
conserved acidic residue (glutamate) of TM6 holds the cytosolic ends of the two helices 
together, which, in turn, helps to stabilize the receptor in an inactive conformation. 
Disruption of this interaction is a known cause of constitutive GPCR activity [58]. 
Interestingly, SmGAR contains several amino acid substitutions that could interfere with 
formation of the ionic lock. Of note is the absence of the critical TM6 glutamate, which is 
replaced with an alanine in SmGAR, and a Phe→Cys substitution near the interacting site of 
TM3. These differences could help to explain the receptor’s propensity towards spontaneous 
activation. In vertebrate muscarinic receptors, Phe→Cys and Glu→Ala point mutations at 
these same positions both caused significant constitutive activity, most likely due to 
destabilization of bonding interactions that favor the off-state of the receptor [58]. 
Interestingly, the Ascaris GAR receptor carries nonconservative substitutions at these two 
sites and also displays a significant level of constitutive activity in the yeast expression 
system [28]. Moreover, our sequence analyses show that most invertebrate GAR-like 
sequences analyzed carry the Glu→Ala substitution in TM6. This conserved substitution 
may suggest a family of constitutively active GARs in invertebrates, or point to a 
fundamental difference in the mechanism of conformational activation between 
invertebrates and vertebrates.
To further investigate the high basal activity of SmGAR we repeated assays in the presence 
of predicted cholinergic inverse agonists. As explained earlier, inverse agonists are 
compounds that display a negative intrinsic activity - they preferentially bind to and stabilize 
the inactive conformation of a receptor, thus reducing basal activity [48]. Often compounds 
that act as competitive antagonists will display inverse agonism when tested on 
constitutively active receptors [48]. Here we examined the response of SmGAR to three 
drugs with known anti-cholinergic activity, atropine, pirenzepine and promethazine. The 
latter was tested because it is a potent inhibitor of the Ascaris GAR-like receptor [28] and 
we questioned whether the drug might also recognize SmGAR. The results showed that 
atropine and promethazine abrogated the high basal activity of SmGAR in a dose-dependent 
manner. These effects are consistent with inverse agonism (rather than antagonism) because 
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the inhibition occurred in the absence of added ACh. Moreover the drug effects are 
selective. Whereas atropine and promethazine decreased basal activity, pirenzepine had no 
significant effect, possibly because it does not recognize the inactive form of the receptor. 
Combined with the unusual structural features of SmGAR discussed above, the response to 
these drugs strongly suggests that the schistosome receptor has intrinsic constitutive activity. 
However, we cannot rule out the possibility of other factors contributing to high basal 
activity, such as receptor overexpression or possibly non-specific activation by some 
unknown factor in the yeast system. Though the full significance of these findings remains 
unclear, the possibility that SmGAR has constitutive activity merits further investigation, 
especially if the receptor is responsive to inverse agonists as suggested by our data. Inverse 
agonists are increasingly recognized for their therapeutic benefits in a variety of human 
diseases [48, 59] and are potential tools for anthelmintic drug discovery. Future studies of 
SmGAR pharmacology will need to incorporate inverse agonist screens, together with 
conventional (competitive) antagonist assays, so as to identify specific receptor inhibitors.
Having characterized SmGAR in vitro, we began to investigate the potential role of the 
receptor in the worm using RNAi. Given that the receptor is upregulated in early larval 
stages [10] and ACh is well known to control worm movement, we questioned whether 
SmGAR might play a role in the control of larval motility. RNAi is well established in 
schistosomes [60] and has been successful in elucidating the role of neuronal proteins in 
motor function [17, 22, 38]. Here, we modified a previously developed RNAi behavioral 
assay [17, 38] to assess the role of SmGAR in larval schistosomulae. Transcriptional 
profiling of SmGAR indicates that it is most highly expressed in cercariae and first 24 hours 
of the schistosomulae stage [10]. Therefore, transfected schistosomulae were assayed for 
motility within the first 24 hours of transformation. Treatment of schistosomulae with 
SmGAR siRNA caused a significant decrease in motor activity when compared to control 
animals, and this correlated with near complete knockdown of the transcript, as determined 
by RT-qPCR. The results suggest that SmGAR does play a role in motor control in the 
young larvae and its activity stimulates larval movement, since the RNAi phenotype was 
clearly hypoactive.
The RNAi phenotype of SmGAR may seem surprising at first, given that ACh is known to 
inhibit schistosome movement. Removal of an inhibitory mechanism would be expected to 
increase motility, whereas the opposite was observed. To explain the results it is important 
to keep in mind that SmGAR is one of many cholinergic receptors in schistosomes [7] and 
the flaccid paralysis caused by ACh in vitro [19, 20] is likely due to stimulation of multiple 
receptors all at once. Some of these receptors do have inhibitory effects on movement [22] 
but there could be stimulatory pathways that were missed in the earlier studies. Based on the 
RNAi data, SmGAR is the first example of a cholinergic receptor that stimulates 
schistosome motor activity, at least in the young larvae. How the receptor is able to 
influence movement is unknown at present. In C. elegans, GARs control locomotion 
indirectly by modulating neuronal output to the muscles. The C. elegans GAR-2 receptor, in 
particular, is expressed on cholinergic motorneurons and acts to suppress the activity of ACh 
as a form of negative feedback mechanism [52]. If SmGAR functions in a similar manner, 
then the hypoactive RNAi phenotype could be explained by loss of the negative feedback 
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provided by the receptor, which would result in increased ACh signaling and reduced 
movement in the RNAi-abrogated animals. However more studies are needed to elucidate 
the exact mode of action of SmGAR.
In conclusion, we have described the cloning and first functional characterization of a new 
cholinergic GPCR in S. mansoni. The results identify a receptor that has intrinsic 
constitutive activity but can be further and selectively activated by ACh. SmGAR shares 
high structural homology with GAR receptors in C. elegans and RNAi experiments suggest 
an important role in motor control, similar to nematode GARs. Given these unique qualities 
and the importance of motor function to schistosome survival, we believe that SmGAR 
merits further investigation as a novel antischistosomal drug target.
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Highlights
• SmGAR is a new G protein-coupled acetylcholine receptor of Schistosoma 
mansoni
• SmGAR has constitutive activity and can be further activated by acetylcholine
• The cholinergic drug atropine has inverse agonist activity towards SmGAR
• RNAi targeting SmGAR produced a hypoactive phenotype in cultured 
schistosomula
• SmGAR is a potential candidate for anti-schistosomal drug targeting.
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Figure 1. SmGAR is structurally related to acetylcholine receptors from other species
A bootstrapped, neighbor-joined phylogenetic tree was generated from a structural 
alignment of SmGAR and putative homologs from vertebrates, nematodes and 
Platyhelminthes. The tree is outgroup-rooted to the human serotonergic 5-HT2 receptor 
(Accession# P28223) and was visualized using FigTree v3.0. Two larger groupings of 
receptors can be seen. The vertebrate muscarinic acetylcholine receptors (mAChRs) (green 
box) separate into their canonical subtypes, M1/M3/M5 (top) and M2/M4 (bottom) and also 
include the closely related C. elegans GAR-3 receptor. The remaining invertebrate G-
protein-linked acetylcholine receptors (GARs) show a further division into the nematode 
GARs and predicted flatworm GARs, including SmGAR (starred). Species abbreviations are 
as follows: Hu, Homo sapiens; Sus, Sus scofra; Cele, Caenorhabditis elegans; Ascaris, 
Ascaris suum, Cs, Clonorchis sinensis; Tsm, Taenia solium; Egr, Echinococcus granulosus; 
Sm, Schistosoma mansoni (see Table S1 for accession numbers of aligned sequences).
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Figure 2. SmGAR forms a constitutively active receptor that responds selectively to acetylcholine
(A) Yeast cells were transformed with SmGAR expression plasmid (black bars) or empty 
plasmid (mock, red bars). Cells were then assayed for receptor activity in the presence of 
test substances each at 10−4 M or vehicle (water). The results are from a single clone of 
SmGAR but are representative of 3 separate clones. *** Significantly different from water-
treated control at P< 0.0001. ACh (B) and carbachol (C) activate SmGAR-expressing cells 
(black triangles) in a concentration-dependent manner. No effect was observed in the mock 
control at any of the concentrations tested (red squares).
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Figure 3. Atropine and promethazine inhibit SmGAR constitutive activity
SmGAR-expressing yeast were treated with increasing concentrations of anticholinergic 
drugs in the absence of ACh in order to assay for inverse agonism. Atropine (A) and 
promethazine (B) both inhibited the high basal activity of SmGAR in a dose-dependent 
manner whereas pirenzepine (C) had no significant effect up to 100 μM.
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Figure 4. Non-conservative amino acid substitutions may contribute to constitutive activity in 
SmGAR
(A) A homology model of SmGAR (red) was superimposed onto the crystal structure of the 
rat M3 muscarinic receptor (4daj) (blue). The SmGAR model shows a typical topology of 
Family A GPCRs, including the canonical 7 transmembrane (TM) domains. Residues of the 
predicted “ionic lock” of Family A GPCRs are shown at the cytosolic ends of TM 3 and TM 
6. Residue R3.50 corresponds to Arg2483.50 in SmGAR and Arg1653.50 in the rat M3 
receptor. E6.30 refers to Glu4856.30 of the rat M3 receptor and A6.30 is the corresponding 
alanine in SmGAR (Ala8486.30). (B) Structural alignment of vertebrate and invertebrate 
muscarinic receptors showing a portion of TM 3 and TM6. The numbers describe the 
relative positions of amino acids of interest in each TM helix, according to the Ballasteros 
and Weinstein system [33], as described in the text. Mammalian muscarinic receptors are 
identified according to subtype, M1–M5; Invertebrate receptors are listed as GAR (G 
protein-coupled acetylcholine receptor) or mAChR (muscarinic acetylcholine receptor). 
Species abbreviations are as described in Fig. 1 and accession numbers are provided in 
Table S1.
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Figure 5. Silencing of SmGAR affects the motor behavior of S. mansoni schistosomulae
Freshly transformed schistosomulae were treated with 50 nM of either SmGAR-specific 
siRNA or nonsense (irrelevant) scrambled siRNA. 24 hours post-transfection 
schistosomulae were assayed for motor phenotype or collected for confirmation of silencing 
at the transcript level (A) Suppression of SmGAR in early larval schistosomulae produces a 
hypomotile phenotype. Animals treated with SmGAR-specific siRNA show a 70% reduction 
in the frequency of body movements when compared to the scrambled siRNA negative 
control. (B) RNA from treated parasites was oligo-dT reverse-transcribed and the resulting 
cDNA was used as a template for quantitative real-time PCR (qPCR). Primers targeting 
SmGAR or an off-target (irrelevant) schistosome gene (SmACC-1 Accession# KF694748) 
were used for qPCR amplification and the data were normalized to a housekeeping gene 
(GAPDH, Accession # M92359). Expression of SmGAR and the irrelevant off-target control 
were calculated as % remaining expression in the siRNA-treated samples relative to the 
scrambled control, using the Pfaffl’s method.
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